- Home
- Companies
- usa california
- in vivo study
Refine by
In Vivo Study Suppliers In Usa California
5 companies found
based inSan Carlos, CALIFORNIA (USA)
Developing live biotherapeutics to prevent and treat diseases of high unmet medical need. We leverage our deep knowledge of the human microbiome and its regulatory and developmental functions to develop live biotherapeutic products (LBPs) and ...
Siolta’s Precision Symbiotics Platform enables rapid LBP development. A platform focused on translating microbiome science into novel therapeutics for a healthier world. Siolta’s patient-centric platform leverages our internal expertise ...
based inBrea, CALIFORNIA (USA)
NuLiv Science is a growing team of scientists, innovators, and creatives focused on developing and communicating the power of our patented ingredients. From humble beginnings starting in 1997, NuLiv Science has grown into a full range ingredient ...
InnoSlim® is a pharmaceutical-grade glucose and lipid metabolic regulator through activation of the adiponectin and AMPK signaling ...
based inFremont, CALIFORNIA (USA)
AnaSpec, a subsidiary of Kaneka Eurogentec, is a globally recognized biotechnology company that manufactures and sells custom and catalog Peptides, Fluorogenic and FRET Assay Kits, Fluorescent Dyes, Amino Acids and more,? for research use, drug ...
Myelin Oligodendrocyte Glycoprotein (MOG) is a member of the immunoglobulin superfamily and is expressed exclusively in the central nervous system (CNS). Although MOG protein constitutes only 0.01-0.05% of the CNS myelin proteins, it was ...
based inSan Francisco, CALIFORNIA (USA)
Biotechnology is leading the most important scientific revolution since computing. R&D is the key to unleashing biotechnology’s potential to radically transform our world, but software hasn’t kept up with science. Scientists deserve and urgently ...
Manage in vivo studies with modern software designed for data capture, collaboration, and ...
based inCarlsbad, CALIFORNIA (USA)
Qualigen is a biotechnology company focused on the development of novel therapeutic products for the treatment of cancer and infectious diseases, as well as expansion of its flagship FastPack diagnostic platform. The FastPack line of FDA-cleared and ...
Qualigen licensed the G4 selective transcription inhibitor platform from University College London (UCL) in 2022. The licensed technology comprises lead compound QN-302 (formerly SOP1812) and back-up compounds that target regulatory regions of ...